Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Henry, S. P.
Right arrow Articles by Levin, A.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henry, S. P.
Right arrow Articles by Levin, A.A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Mutagenesis, Vol. 17, No. 3, 201-209, May 2002
© 2002 UK Environmental Mutagen Society/Oxford University Press

Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide

Scott P. Henry,5,6, D.K. Monteith,1,6, J.E. Matson, B.H. Mathison, K.S. Loveday,2, R.A. Winegar,3, J.E. Matson, P.S. Lee,4, E.S. Riccio,4, J.P. Bakke,4 and A.A. Levin

ISIS Pharmaceuticals, Carlsbad Research Center, 2292 Faraday Avenue, Carlsbad, CA 92008, USA

ISIS 2302, a phosphorothioate oligodeoxynucleotide with antisense activity against human ICAM-1 mRNA, was evaluated in a battery of tests to assess genotoxic potential. There was no evidence of genotoxicity in three in vitro studies performed: (i) a bacterial reverse mutation test; (ii) a chromosomal aberration test in Chinese hamster ovary cells; (iii) a mammalian cell gene mutation assay in L5187Y cells. Additionally, there was no in vivo evidence of genetic toxicity in a bone marrow micronucleus study in male and female mice. For all tests, top concentrations or doses assessed met harmonized regulatory guidelines. The cellular uptake of ISIS 2302 into target cells was confirmed using capillary gel electrophoresis and immunohistochemistry. Intracellular uptake into CHO cells, L5187Y cells, Salmonella typhimurium TA98 and bone marrow was concentration- and time-dependent. Consistent with what is known about the physical and chemical properties of phosphorothioate oligodeoxynucleotides, there was no evidence of genotoxicity in any of the assessed end-points. Furthermore, the absence of genotoxicity could not be ascribed to test system insensitivity or to an absence of exposure of the test system to ISIS 2302.

1 Present address: Sierra Biomedical, 10326 Roselle Street, San Diego, CA, USA

2 Present address: Transkaryotic Therapies Inc., 195 Albany Street, Cambridge, MA, USA

3 Present address: Midwest Research Institute, 1470 Treeland Boulevard South East, Palm Bay, FL, USA

4 Present address: SRI International, 333 Ravenwood Avenue, Menlo Park, CA 94025, USA

5 To whom correspondence should be addressed. Tel: +1 760 603 3813; Fax: +1 760 603 3862; Email: shenry{at}isisph.com

6 These authors contributed equally to the data collection and presentation in this manuscript and are to be considered joint first authors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.